Prevention of Deep Vein Thrombosis (DVT) in Patients undergoing Total Knee Replacement (TKR)Surgery with Low Molecular Weight Heparin (LMWH) or outpatient Calf Compression Device (CCD) after a short course of LMWH: a randomized prospective study
Prevention of Deep Vein Thrombosis (DVT) in Patients undergoing Total Knee Replacement (TKR)Surgery
Southern Sydney Hematology
100 participants
Dec 28, 2011
Interventional
Conditions
Summary
This study hypothesises that shorter duration low molecular weight therpay is as effective as standard therapy in post operative orthopaedic DVT prophylaxis. There will be no significant difference in the incidence of post operative thrombotic events such as DVTs and PE. There mat be added advantages of reduced leg swelling and hence pain with the use of mobile calf compressor device as an outpatient.
Eligibility
Inclusion Criteria7
- age 18-90
- no personal/family hx thrombophilia
- BMI <35
- english speaking
- no anti-coagulation for other reasons
- no acute clotting problem
- undergoing elective total knee replacement surgery
Exclusion Criteria6
- age <18, >90
- BMI >35
- known history of thrombophilia
- already on anti-coagulation
- active malignancy or bleeding disorders
- unfit to undergo surgical procedure (TKR)
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
The usual practice of low molecular heparin therapy after orthopedic surgery to reduce risk of DVT and PE remains controversial in terms of length of therapy. This study is aimed at answering this question by reducing the length of therapy from 2 weeks to 1 week, without compromising safety in terms of increasing risk of clotting complications. The usual therapy involves enoxaparim 0.5 mg/kg,daily, commencing 8-12 hours post op, given subcutaneously. The only difference between the study groups was the length of the therapy but given daily.
Locations(2)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12613000240741